Sartorius stock reports 8.10 percent sales growth, rises 1.70 percent pre-market
Published on 10/22/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth update for the group
- The issuer reported EUR 2,737.20 million in nine-month sales on October 22, 2026.
- Sartorius will discuss its nine-month results in a conference call on October 22, 2026, at 1:00 p.m. CEST.
- Sartorius stock trades pre-market at EUR 265.55 at 7:59 a.m. CEST at Lang & Schwarz on October 22, 2026, 1.70 percent above the Xetra close of October 21, 2026.
Sartorius reported nine-month sales growth of 8.10 percent in constant currencies excluding customer compensation for U.S. tariffs on October 22, 2026, in an issuer release distributed through EQS News. Sartorius stock trades pre-market at EUR 265.55 at 7:59 a.m. CEST at Lang & Schwarz on October 22, 2026, 1.70 percent above the Xetra close of October 21, 2026 (EUR 261.10).
Nine-month growth and guidance
The Sartorius Group generated EUR 2,737.20 million in sales revenue during the first nine months of 2026, while underlying EBITDA rose 6.90 percent to EUR 827.80 million and the margin increased to 30.20 percent, according to the issuer release distributed by EQS News. Management confirmed its 2026 guidance and refined expectations for the Lab Products & Services division and capital expenditure. Group sales growth excluding tariff effects is expected around the midpoint of a 5.00 percent to 9.00 percent range, while the Lab Products & Services division is expected around the upper end of its 4.00 percent to 6.00 percent range.
Ahead of the Xetra open
The pre-market indication is EUR 4.45 above the Xetra close of October 21, 2026. The bid is EUR 263.90 and the ask is EUR 267.20, a spread of 1.24 percent. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Sartorius stock.
Business and today's agenda
Sartorius supplies laboratory instruments and consumables for research and quality-assurance laboratories and technologies for biopharmaceutical manufacturing, earning revenue from products and related services. The company is scheduled to hold a conference call on its nine-month results on October 22, 2026, at 1:00 p.m. CEST, according to its Investor Relations page. Market context: Market report DAX.
